(Q36893286)

16 August 2017

1 reference

title

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia (English)

1 reference

16 August 2017

0 references

0 references

1 reference

D Taylor

12

0 references

author name string

A H Barnett

1

1 reference

16 August 2017

P Mackin

2

1 reference

16 August 2017

I Chaudhry

3

1 reference

16 August 2017

A Farooqi

4

1 reference

16 August 2017

R Gadsby

5

1 reference

16 August 2017

A Heald

6

1 reference

16 August 2017

J Hill

7

1 reference

16 August 2017

H Millar

8

1 reference

16 August 2017

R Peveler

9

1 reference

16 August 2017

A Rees

10

1 reference

16 August 2017

V Singh

11

1 reference

16 August 2017

J Vora

13

1 reference

16 August 2017

P B Jones

14

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Journal of Psychopharmacology

16 August 2017

1 reference

16 August 2017

21

1 reference

16 August 2017

4

1 reference

16 August 2017

357-373

1 reference

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

16 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Excess mortality of schizophrenia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Waist circumference as a measure for indicating need for weight management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Amisulpride is an "atypical" antipsychotic associated with low weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Different effects of antipsychotic drugs on insulin release in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Mortality in a cohort of patients with schizophrenia: a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

The treatment of unrelated disorders in patients with chronic medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Risk factors indicating recurrent myocardial infarction after recovery from acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Testing for diabetes in hospitalised patients prescribed antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

The assessment of insulin resistance in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Bodyweight gain with atypical antipsychotics. A comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107075509

21 January 2018

Identifiers

DOI

10.1177/0269881107075509

1 reference

16 August 2017

1 reference